Sanofi: Disclosure of trading in own shares

Q3 2026: double-digit growth in sales and business EPSFY 2026: guidance upgraded October 30, 2026 Q3 sales growth of 14.3% at CER1 and business earnings per share (EPS)2 of €3.55 Pharma launches...

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing...